van Steenkiste, Job
Verberk, Iris
Versmissen, Jorie
Dohmen, Daan
Jainandunsing, Sjaam
Article History
Received: 15 December 2023
Accepted: 19 February 2024
First Online: 4 April 2024
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of The Maasstad Hospital, The Netherlands (identifier L2023003). This study was assessed not to be subject to the Dutch Medical Research Involving Human Subjects Act (WMO) by the Medical Ethics Committee United (MEC-U, identifier W23.091). All methods described in this study were performed in accordance with relevant guidelines and regulations, including Good Clinical Practice guidelines and applicable laws and regulations. All patients consented to participate prior to the beginning of the pilot project and written informed consent was obtained for all involved patients to use the data for this study after the pilot project was finished.
: Not applicable.
: Job van Steenkiste, MD: nothing to declare. Iris Verberk, MD, PhD: nothing to declare. Jorie Versmissen, MD, PhD: nothing to declare. Daan Dohmen, Prof, PhD: Prof. D. Dohmen is the CEO of Luscii, the involved HBPT platform used for the purpose of the described pilot project. There was no financial support provided by Luscii to facilitate this pilot study or the pilot project. Sjaam Jainandunsing, MD, PhD: nothing to declare.